Cargando…
Hypoparathyroidism: an uncommon adverse effect of treatment with durvalumab
SUMMARY: Immune checkpoint inhibitors (ICIs) are monoclonal antibodies approved for the treatment of numerous cancer types. Toxicities induced by ICIs may affect any organ system and manifest as endocrinopathy. The main side effects related to treatment are immune-related adverse events (irAEs), esp...
Autores principales: | Kreze, Alexander, Homer, Matěj, Barešová, Tereza, Klemperová, Kristina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259288/ https://www.ncbi.nlm.nih.gov/pubmed/37435467 http://dx.doi.org/10.1530/EO-22-0047 |
Ejemplares similares
-
Strongyloides—An uncommon cause of eosinophilia whilst on durvalumab
por: Quah, Gaik Tin, et al.
Publicado: (2022) -
Hypoparathyroidism: An Uncommon Complication Associated With Immune Checkpoint Inhibitor Therapy
por: El Kawkgi, Omar M., et al.
Publicado: (2020) -
An Uncommon Case of Myocarditis Secondary to Durvalumab Plus Tremelimumab
por: Diaz-Rodriguez, Porfirio E, et al.
Publicado: (2023) -
Retinal Vasculitis Secondary to Durvalumab
por: R. Andrade, Antonio, et al.
Publicado: (2020) -
Statin-Associated Necrotizing Autoimmune Myositis Complicated by an Uncommon Adverse Effect to Treatment
por: Fung, Brian M., et al.
Publicado: (2019)